A Third of European Senior AI Professionals Don’t Believe That C-Suite Leaders Understand the Risks and Benefits of AI
Dataiku, the platform for Everyday AI, together with Databricks, today revealed the findings from a survey of global senior AI professionals at large enterprises throughout Europe. The respondents1 answered questions on Generative AI, spend on AI tools and ROI, AI use case reach, and more.
While the global survey of 400 respondents revealed broad enthusiasm and action around Generative AI, the European results showed that European senior AI professionals are more likely to see Generative AI as a revolution that will change the way we work (29%), compared to the U.S. (23%). European data leaders are more likely to have clear processes for delivering AI projects and putting them into production (57%), compared to the U.S. (43%).
However, European respondents also feel current AI regulation is not sufficient, with just under half agreeing that AI requires more regulation, and a third answering that they do not believe that organizational leaders (i.e., C-Suite) understand the risks and benefits of AI.
“We believe an ongoing dialogue and collaboration in AI is needed, and these findings show that data leaders across Europe and the U.K. are not insensitive to the potential downsides of this technology,” said Shaun McGirr, Field Chief Data Officer at Dataiku. “Together, we need to increase public awareness about the potential impact of AI on society and future generations. Now is the time to have an honest conversation about how we want this technology to be used.”
The European results form part of a larger global survey of data leaders across a range of enterprises and industries, which was run in June 2023 to explore AI adoption and perceptions. Respondents were closely divided on AI maturity, with nearly half (48%) reporting that they are embedding or expanding data science and AI, while 51% are still experimenting or establishing AI. However, tracking value trailed deployments, with nearly two in five (37%) data leaders accounting for the value of data science and AI initiatives with consistent frameworks, or accounting for AI on the balance sheet like other strategic initiatives. Fifty five percent have an inconsistent tracking system or only record results anecdotally.
"These findings demonstrate the significant interest in generative AI but also the accompanying challenges, from data access and privacy to regulation," said Prem Prakash, Head of AI Marketing at Databricks. "As we navigate these challenges, our shared mission with Dataiku stands firm: to democratize data and AI, enabling every organization to build their generative AI solutions securely and cost-effectively."
Dataiku was named Databricks 2023 AI Partner of the Year at the Data + AI Summit in San Francisco last month for its collaborative technology which makes it easy for customers to deploy Generative AI to turn data into powerful business results. Get started with Databricks and Dataiku and read how you can Have your Cake and Eat It Too With Dataiku and Databricks.
- Download the comprehensive report to explore the full landscape of AI adoption and perceptions.
- Join the upcoming Dataiku + Databricks survey results webinar, AI by the Numbers: See How You Stack Up in the Race to Generative AI.
Dataiku is the platform for Everyday AI, enabling data experts and domain experts to work together to build data into their daily operations, from advanced analytics to Generative AI. Together, they design, develop and deploy new AI capabilities, at all scales and in all industries. Organizations that use Dataiku enable their people to be extraordinary, creating the AI that will power their company into the future.
Founded in 2013, Dataiku has proven its ability to develop its founding vision for Everyday AI, and to execute on its growth. With more than 500 customers and more than 1,000 employees, Dataiku is proud of its rapid growth and 95% retention of Forbes Global 2000 customers. Connect with Dataiku on their blog, X (@dataiku) and on LinkedIn.
1 Respondents are manager level or higher, come from the U.S., EMEA, and APAC, and work at organizations with >$3 billion in annual revenue. See https://pages.dataiku.com/dataiku-databricks-ai-survey page 26 “About the Survey” for additional details about respondents and methodology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUMA Called Ambassadors From All Around the World to Form “Class of 23”1.10.2023 13:00:00 EEST | Press release
Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231001418878/en/ Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. (Photo: Business Wire) 2023 means a long journey for PUMA, which was made with the remarkable people behind it. “Class of 23” is the right way to celebrate the inspiring ambassadors and talents PUMA has collaborated with over the past 75 years. Each talent, from Neymar Jr. and Pamela Reif to Gianmarco Tamberi and Winnie Harlow, was captured in a personalized way, wearing their favorite PUMA beanies from the 2023 collection to show their membership in the grand PUMA family. “Our PUMA family is the heartbeat of our brand, co-created with the brilliance
Optomind and MaxLinear announce collaboration on PAM4 112Gbps OSFP 800Gbps SR8 transceiver solution at ECOC Exhibition 20231.10.2023 09:00:00 EEST | Press release
Optomind and MaxLinear will be demonstrating 800Gbps OSFP active optical cables (AOC) and SR8 optical transceivers at ECOC 2023 Exhibition, in Glasgow, Scotland, October 2-4 (Booth #775, Optomind; #776, MaxLinear). Optomind has developed the best-in-class PAM4 100Gbps/lane SR optical transceivers and AOCs using MaxLinear's 5nm Keystone PAM4 DSP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230930086952/en/ Advancing data transmission rates to 100Gbps per lane drastically transforms the ecosystem of data centers, especially AI/ML and HPC. Training AI and GPT workloads drive huge and high-density networks utilizing large numbers of servers connected together through rack switches over short reach links. The low-power, high-performance AOCs and transceivers that Optomind and MaxLinear have developed together are ideal for these applications. Optomind selected MaxLinear's 5nm Keystone PAM4 DSP as the best-in-class solution for
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an
Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release
GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom